TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/06/2024
Back to search
Official data from USPTO
NKGEN BIOTECH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NKGEN BIOTECH
ST13
US500000090514320Class
5, 42
Filing
90514320
Registration
6958359
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
12/10/2024
Trademark type
Word
Nice classes
5, 42
Filing date
02/05/2021
Registration date
01/17/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/17/2023
Last transaction
12/10/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/06/2021
First use in commerce
04/06/2021
Drawing code
4
Owner type
03
Owner location
SANTA ANA, CA, US
Examiner
LEE, JEANIE H
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NKGEN BIOTECH, INC.
NKMAX CO., LTD.
Representatives
Deborah L. Corpus Chrisman Gallo Tochtrop LLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical preparations for animals; Pharmaceutical preparationsimmunomodulators; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; biopharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; stem cells for medical purposes; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of immune system related diseases and disorders
Class 42
development of cell therapy products; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes; medical and pharmacological research services; medical research services; development of biotechnology; biotechnological research; cell separation research services; technological research in the field of cell therapymedicinepharmacologybiotechnology
Publications
History of USPTO decisions and trademark events.
41 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/06/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/06/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/17/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/17/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/10/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/17/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/16/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
11/16/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/13/2022
GNFR
FINAL REFUSAL E-MAILED
10/13/2022
CNFR
SU - FINAL REFUSAL - WRITTEN
10/13/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/21/2022
ALIE
ASSIGNED TO LIE
09/21/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/16/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/14/2022
GNRT
NON-FINAL ACTION E-MAILED
07/14/2022
CNRT
SU - NON-FINAL ACTION - WRITTEN
07/14/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/07/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/06/2022
IUAF
USE AMENDMENT FILED
05/20/2022
EISU
TEAS STATEMENT OF USE RECEIVED
05/20/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/15/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/21/2021
PUBO
PUBLISHED FOR OPPOSITION
12/21/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/01/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/15/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/11/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/11/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/10/2021
GNRT
NON-FINAL ACTION E-MAILED
09/10/2021
CNRT
NON-FINAL ACTION WRITTEN
09/10/2021
DOCK
ASSIGNED TO EXAMINER
08/28/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/11/2021
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
03/24/2021
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/24/2021
NWAP
NEW APPLICATION ENTERED
02/09/2021
Continuous trademark protection
Get notified about every new filing that threatens NKGEN BIOTECH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.